Section 1 of 4Overview

Overview

An approved amylin analog used with mealtime insulin in selected adults with type 1 or type 2 diabetes.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

It complements insulin by suppressing post-meal glucagon, slowing gastric emptying and increasing satiety.

PubChem CID 70691388; C171H267N51O53S2; 3949 Da.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; adjunct to mealtime insulin).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. The label starts at 15 micrograms before major meals in type 1 diabetes and 60 micrograms before major meals in type 2 diabetes, with simultaneous 50% mealtime-insulin reduction and label-defined titration.

Section 4 of 4Safety boundary

Safety boundary

The boxed warning concerns severe insulin-induced hypoglycemia, especially in type 1 diabetes; careful patient selection and insulin adjustment are central to the label.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.